1. Home
  2. AXDX vs RFL Comparison

AXDX vs RFL Comparison

Compare AXDX & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AXDX
  • RFL
  • Stock Information
  • Founded
  • AXDX 1982
  • RFL 2017
  • Country
  • AXDX United States
  • RFL United States
  • Employees
  • AXDX N/A
  • RFL N/A
  • Industry
  • AXDX Biotechnology: Laboratory Analytical Instruments
  • RFL Real Estate
  • Sector
  • AXDX Industrials
  • RFL Finance
  • Exchange
  • AXDX Nasdaq
  • RFL Nasdaq
  • Market Cap
  • AXDX 44.5M
  • RFL 48.4M
  • IPO Year
  • AXDX 1996
  • RFL N/A
  • Fundamental
  • Price
  • AXDX $1.85
  • RFL $1.84
  • Analyst Decision
  • AXDX Hold
  • RFL
  • Analyst Count
  • AXDX 1
  • RFL 0
  • Target Price
  • AXDX $1.00
  • RFL N/A
  • AVG Volume (30 Days)
  • AXDX 61.8K
  • RFL 26.3K
  • Earning Date
  • AXDX 11-07-2024
  • RFL 12-12-2024
  • Dividend Yield
  • AXDX N/A
  • RFL N/A
  • EPS Growth
  • AXDX N/A
  • RFL N/A
  • EPS
  • AXDX N/A
  • RFL N/A
  • Revenue
  • AXDX $11,909,000.00
  • RFL $637,000.00
  • Revenue This Year
  • AXDX $1.42
  • RFL N/A
  • Revenue Next Year
  • AXDX $4.09
  • RFL N/A
  • P/E Ratio
  • AXDX N/A
  • RFL N/A
  • Revenue Growth
  • AXDX N/A
  • RFL 128.32
  • 52 Week Low
  • AXDX $0.73
  • RFL $1.29
  • 52 Week High
  • AXDX $5.52
  • RFL $2.50
  • Technical
  • Relative Strength Index (RSI)
  • AXDX 48.99
  • RFL 46.69
  • Support Level
  • AXDX $1.77
  • RFL $1.74
  • Resistance Level
  • AXDX $2.04
  • RFL $1.96
  • Average True Range (ATR)
  • AXDX 0.11
  • RFL 0.10
  • MACD
  • AXDX -0.01
  • RFL -0.01
  • Stochastic Oscillator
  • AXDX 29.63
  • RFL 40.00

About AXDX Accelerate Diagnostics Inc.

Accelerate Diagnostics Inc is an in vitro diagnostics company that specializes in rapid diagnostics for infectious pathogens. The firm's core platform, the Accelerate ID/AST System, determines whether live bacterial or fungal cells in a patient sample are susceptible to a particular antibiotic. This test is performed on pathogens that are commonly associated with serious infections and can deliver results more quickly than traditional methods, such as bacterial culturing. The system can analyze a positive blood culture sample in approximately five hours, which is faster than traditional testing techniques. The company earns majority of its revenue from domestic market.

About RFL Rafael Holdings Inc. Class B

Rafael Holdings Inc, through its subsidiaries, is a clinical stage, oncology-focused pharmaceutical company committed to the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. The company is a significant investor in two clinical stage oncology companies, Cornerstone Pharmaceuticals, Inc., and LipoMedix Pharmaceuticals Ltd.

Share on Social Networks: